PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
REGULATORY
Second Applicant from Pharma Companies to Use MID-NET: PMDA
The Pharmaceuticals and Medical Devices Agency (PMDA) has received a second application from a pharma company to use its MID-NET medical information database since its official launch in April, an official told Jiho. The deadline for the third round of…
To read the full story
Related Article
- MSD to Tap MID-NET Database for Erelsa/Grazyna in 3rd Private Sector Use
January 29, 2019
- Pfizer to Use MID-NET Database for Ibrance PMS
September 19, 2018
- First Drug Maker Applies to Use MID-NET: PMDA
August 7, 2018
- PMDA Reveals First 2 Cases of MID-NET Regulatory Use
July 2, 2018
- PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
June 19, 2018
REGULATORY
- Japan Eyes Priority Review for MCMs, Bill Submission Planned for 2027
October 28, 2026
- Panel Member Urges Review of Tavneos Blue Letter Timing
October 28, 2026
- Japan Orders Label Revisions for Leqvio, Amenalief, 2 Other Drugs
October 28, 2026
- AbbVie’s Fast-Acting Botulinum Toxin Boey Wins Japan Panel Backing
October 27, 2026
- LDP Lawmakers Renew Push for Routine HPV Shots for Males by April 2027
October 27, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…